首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >Biodegradable long circulating cellular carrier for antimalarial drug pyrimethamine
【24h】

Biodegradable long circulating cellular carrier for antimalarial drug pyrimethamine

机译:用于抗疟药嘧啶嘧啶的可生物降解的长循环细胞载体

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The objective of the present study was to develop targeted engineered nanoerythrosomes based intravenous formulation of antimalarial drug pyrimethamine. Material and methods: The nanoerythrosomes formulation was developed by sonication method and optimized for effective drug loading at variable drug concentration, surface morphology, viscosity and sedimentation volume. Results: The in vitro drug release of formulated product was found to be delayed after 8 hours, having good stability at 4 ± 1°C and showing controlled in vivo release. Tissue distribution studies showed higher accumulation of drug in the liver (18.71 ± 1.4 μg/ml) (P < 0.05) at 1 hour in case of pyrimethamine-loaded nanoerythrosomes as compared to that in free drug (12.82 ± 0.7 μg/ml). Higher amount of drug, i.e. 14.18 ± 0.9 μg/ml (P < 0.05), was found after 24 hours in the liver in case of pyrimethamine-loaded nanoerythrosomes as compared to free drug concentration of 9.72 ± 0.5 μg/ml). Discussion: Data showed that developed pyrimethamine-loaded nanoerythrosomes hold promise for targeting and controlling the release of drug and for improving treatment of malaria when they are combined with rapid acting antimalarials such as artemisinin. Conclusion: A decrease in the concentration of pyrimethamine in kidneys and lungs after 24 hours was observed as compared to that observed after 1 hour, showing no or little involvement of these organs in the clearance of drug-loaded nanoerythrosomes.
机译:目的:本研究的目的是发展基于抗疟药嘧啶嘧啶的基于静脉内配方的靶向工程纳米瘤。材料和方法:通过超声处理方法开发纳米内容制剂,并针对可变药物浓度,表面形态,粘度和沉降体积进行了优化的有效药物载荷。结果:发现配制产物的体外药物释放在8小时后延迟,在4±1℃下具有良好的稳定性,并在体内释放中显示。与游昔齐胺加载的纳米粥样物(12.82±0.7μg/ ml)相比,组织分布研究显示肝脏中肝脏(18.71±1.4μg/ ml)(p <0.05)的含量较高,在酰齐米的纳米粒子中较高。在肝脏的24小时后,在肝脏的24小时后发现较高量的药物,即14.18±0.9μg/ ml(P <0.05),如吡米甲胺加载的纳米内培养物相比,与游离药物浓度为9.72±0.5μg/ ml)。讨论:数据显示,吡米达胺加载的纳米内容占靶向和控制药物的释放和改善疟疾治疗时的承担承诺,当它们与野生素蛋白等快速作用抗疟药相结合时改善疟疾的治疗。结论:与1小时后观察到24小时后,观察到24小时后酰胺和肺浓度的降低,显示出这些器官在载载纳米内容的间隙中没有或几乎没有参与。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号